Purple Biotech (PPBT) - Total Liabilities
Based on the latest financial reports, Purple Biotech (PPBT) has total liabilities worth $7.91 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Purple Biotech to track the company's year-over-year net asset growth rate.
Purple Biotech - Total Liabilities Trend (2013–2025)
This chart illustrates how Purple Biotech's total liabilities have evolved over time, based on quarterly financial data.
Purple Biotech Competitors by Total Liabilities
The table below lists competitors of Purple Biotech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mobius Investment Trust PLC
LSE:MMIT
|
UK | GBX2.02 Million |
|
Aclarion Inc
NASDAQ:ACON
|
USA | $699.75K |
|
Margaret Lake Diamonds Inc
V:DIA
|
Canada | CA$859.97K |
|
Future Supply Chain Solutions Limited
NSE:FSC
|
India | Rs3.32 Billion |
|
Gafisa S.A
SA:GFSA3
|
Brazil | R$3.20 Billion |
|
VULTUS AB
F:V06
|
Germany | €5.15 Million |
|
A Luzon Real Estate & Finance Ltd
TA:LZNR
|
Israel | ILA33.77 Million |
|
Siwani Makmur Tbk
JK:SIMA
|
Indonesia | Rp261.72 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Purple Biotech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PPBT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Purple Biotech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Purple Biotech (2013–2025)
The table below shows the annual total liabilities of Purple Biotech from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.91 Million | +91.73% |
| 2024-12-31 | $4.13 Million | -58.75% |
| 2023-12-31 | $10.01 Million | +32.97% |
| 2022-12-31 | $7.52 Million | +47.76% |
| 2021-12-31 | $5.09 Million | +25.70% |
| 2020-12-31 | $4.05 Million | +5.03% |
| 2019-12-31 | $3.86 Million | +3.71% |
| 2018-12-31 | $3.72 Million | -33.47% |
| 2017-12-31 | $5.59 Million | +265.60% |
| 2016-12-31 | $1.53 Million | +10.56% |
| 2015-12-31 | $1.38 Million | +40.26% |
| 2014-12-31 | $986.00K | -21.56% |
| 2013-12-31 | $1.26 Million | -- |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more